Lenalidomide Synthon (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4‑CRBN E3 ubiquitin ligase complex. This binding triggers the degradation of transcription factors Ikaros and Aiolos, leading to enhanced immune cell activity, inhibition of angiogenesis, and direct anti‑tumor effects against myeloma and certain myelodysplastic cells.

The specific dose of Lenalidomide Synthon is determined by the prescribing clinician based on the patient’s diagnosis, disease stage, renal function, and other individual factors. Healthcare professionals follow approved dosing guidelines and adjust as needed for safety and efficacy.

Lenalidomide is classified as Pregnancy Category X because it can cause severe birth defects. It is contraindicated in pregnancy, and effective contraception is required for both male and female patients of reproductive potential. Use during breastfeeding is also not recommended.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Lenalidomide belongs to the immunomodulatory drug class, offering a distinct mechanism compared with proteasome inhibitors or monoclonal antibodies. It is often used in combination regimens and provides benefits such as oral administration and immune‑enhancing effects, but the choice of therapy depends on disease characteristics and prior treatments.

Lenalidomide Synthon should be stored at ambient temperature, below 25 °C, in its original container. The packaging protects the product from moisture and light, helping maintain its stability throughout its shelf life.

Lenalidomide Synthon is taken orally, usually once daily, with or without food as directed by the prescribing physician. Patients should follow the exact schedule and any special instructions provided by their healthcare professional.

The most serious risks include severe neutropenia or thrombocytopenia, which can lead to infections or bleeding, and venous thromboembolism such as deep‑vein thrombosis or pulmonary embolism. Patients should be monitored closely for signs of infection, bleeding, or clotting events.

Lenalidomide Synthon should not be used by individuals who are pregnant, planning to become pregnant, or are not using effective contraception. It is also contraindicated in patients with known hypersensitivity to lenalidomide or any component of the formulation.